DrugPatentWatch Database Preview

NOXAFIL Drug Profile

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

When do Noxafil patents expire, and what generic alternatives are available?

Noxafil is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. There are eight patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in thirty-four countries.

The generic ingredient in NOXAFIL is posaconazole. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the posaconazole profile page.

Summary for NOXAFIL

International Patents:	135
US Patents:	8
Applicants:	2
NDAs:	3
Suppliers / Packagers:	1
Bulk Api Vendors:	63
Clinical Trials:	15
Patent Applications:	35
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOXAFIL
DailyMed Link:	NOXAFIL at DailyMed

Pharmacology for NOXAFIL

Ingredient-type	Azoles
Drug Class	Azole Antifungal

Synonyms for NOXAFIL

1-((1S,2S)-1-Ethyl-2-hydroxypropyl)-4-{4-[4-(4-{[(5S,3R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1,2,4-triazolin-5-one

171228-49-2

177571-33-4

2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-({4-[4-(4-{1-[(2S,3S)-2-hydroxypentan-3-yl]-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl}phenyl)piperazin-1-yl]phenoxy}methyl)-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol

228P492

3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl)methoxy)phenyl)-1-piperazinyl)phenyl)-2-(1-ethyl-2-hydroxypropyl)-2,4-dihydro-, (3R-(3alpha(1S*,2S*),5alpha))-

4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one

4-(4-(4-(4-(((3R,5R)-5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-5-(2,4-DIFLUOROPHENYL)TETRAHYDROFURAN-3-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-1-((2S,3S)-2-HYDROXYPENTAN-3-YL)-1H-1,2,4-TRIAZOL-5(4H)-ONE

4-(4-(4-(4-(((3R,5R)-5-(3,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-1-((2S,3S)-2-hydroxypentan-3-yl)-1H-1,2,4-triazol-5(4H)-one

4-(4-(4-(4-(((5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)-tetrahydrofuran-3-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-((2S,3S)-2-hydroxypentan-3-yl)-2H-1,2,4-triazol-3(4H)-one

4-(p-(4-(p-(((3R,5R)-5-(2,4-Difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furyl)methoxy)phenyl)-1-piperazinyl)phenyl)-1-((1S,2S)-1-ethyl-2-hydroxypropyl)-delta(sup 2)-1,2,4-triazolin-5-one

4-[4-(4-{4-[(R)-5-(2,4-difluoro-phenyl)-5-(4,5-dihydro-[1,2,4]triazol-1-ylmethyl)-tetrahydro-furan-3-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-((1S,2S)-1-ethyl-2-hydroxy-propyl)-2,4-dihydro-[1,2,4]triazol-3-one

4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one

4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxy-propyl]-1,2,4-triazol-3-one

4-{4-[4-(4-{[(3R,5R)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2-[(2S,3S)-2-hydroxypentan-3-yl]-1,2,4-triazol-3-one

4-{4-[4-(4-{[(3r,5r)-5-(2,4-difluorophenyl)-5-(1h-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2-[(1s,2s)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3h-1,2,4-triazol-3-one

6TK1G07BHZ

AB0015409

AB01274762_02

AB01274762-01

AC-1350

AC1LAHLQ

ACN-040495

AK-72814

AKOS005145917

BC677686

BDBM50181473

C37H42F2N8O4

CHEBI:64355

CHEMBL1397

CP0094

CS-0998

CTK6B1621

D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(1-((1S,2S)-1-etyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)-

D02555

DB01263

FT-0657137

HE073055

HE317797

HSDB 7421

HY-17373

KS-00000GY1

KS-1413

M842

MFCD00941162

MMV688774

MolPort-006-666-426

Noxafil (TN)

P-7020

P2477

pasaconazole

PB30668

posaconazol

Posaconazole

Posaconazole (JAN/USAN/INN)

Posaconazole [USAN:INN:BAN]

Posaconazole in combination with MGCD290

Posaconazole SP

Posaconazole, Antibiotic for Culture Media Use Only

Posaconazole, VETRANAL(TM), analytical standard

Posconazole

Q-4359

RAGOYPUPXAKGKH-XAKZXMRKSA-N

RL02201

RTR-007528

s1257

SC-23857

Sch 56592

SCH-56592

SCH56592

SCHEMBL991747

Schering 56592

Spriafil

ST24042909

TR-007528

UNII-6TK1G07BHZ

ZINC3938482

US Patents and Regulatory Information for NOXAFIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;IV (INFUSION)	205596-001	Mar 13, 2014		RX	Yes	Yes			Y	Y
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006		RX	Yes	Yes			Y	Y
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;IV (INFUSION)	205596-001	Mar 13, 2014		RX	Yes	Yes			Y
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006		RX	Yes	Yes			Y	Y

  Purchase this report

or, see our see our flat-rate plans

Expired US Patents for NOXAFIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;IV (INFUSION)	205596-001	Mar 13, 2014
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013

Paragraph IV (Patent) Challenges for NOXAFIL

Drugname	Dosage	Strength	RLD	Submissiondate
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24
	Delayed-release Tablets	100 mg		2014-06-16
	Oral Suspension	40 mg/mL		2011-02-28

Non-Orange Book US Patents for NOXAFIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
5,710,154	Tetrahydrofuran antifungals
6,713,481	Crystalline antifungal polymorph
7,635,773	Sulfoalkyl ether cyclodextrin compositions
5,693,626	Tetrahydrofuran antifungals

  Purchase this report

or, see our see our flat-rate plans

International Patents for NOXAFIL

Country	Document Number	Estimated Expiration
New Zealand	309281
Norway	971218
Taiwan	I311464
European Patent Office	2748205

Supplementary Protection Certificates for NOXAFIL

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0736030/01	Switzerland		FORMER OWNER: SCHERING CORPORATION, US
0219	Netherlands		300219, 20141220, EXPIRES: 20191219
216	Luxembourg		91216, EXPIRES: 20191220
C/GB06/007	United Kingdom		PRODUCT NAME: POSACONAZOLE, OPTIONALLY IN THE FORM OF AN ESTER OR PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/05/320/001 20051025; UK EU/1/05/321/001 20051025